NathanGossaiMD
Pediatric Hematology & Oncology • Minneapolis, MNPediatric Hematologic Oncology
Physician
Dr. Gossai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2525 Chicago Ave
Minneapolis, MN 55404Phone+1 612-813-6100Fax+1 651-220-5147
Summary
- Dr. Nathan Gossai is a pediatric hematologist/oncologist in Minneapolis, MN and is affiliated with multiple hospitals in the area, including Children's Hospitals and Clinics of Minnesota and University of Minnesota Medical Center, Fairview. He received his medical degree from Georgetown University School of Medicine and has been in practice 6 years. He specializes in pediatric hematologic oncology.
Education & Training
University of MinnesotaFellowship, Pediatric Hematology/Oncology, 2013 - 2016- University of MinnesotaResidency, Pediatrics, 2010 - 2013
Georgetown University School of MedicineClass of 2010
Certifications & Licensure
MN State Medical License 2013 - 2025
WI State Medical License 2017 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Award Session Presentation SIOP, 2019
Clinical Trials
- Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome Start of enrollment: 2016 Aug 17
- PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Start of enrollment: 2019 Feb 12
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02
Roles: Contact
Publications & Presentations
PubMed
- 70 citationsMore precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modelingPeter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey
Blood Advances. 2019-11-12 - 50 citationsReducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.Amy K. Keating, Nathan Gossai, Christine L Phillips, Kelly W. Maloney, Kristen Campbell
Blood Advances. 2019-07-09 - 7 citationsMatched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K. Tasian, Maria Luisa Sulis, Kristen E. Stevenson, Traci M. Blonquist
Cancer Discovery. 2021-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
